Prithviraj Bose, MD, and Pankit Vachhani, MD, discuss the limitations of currently approved JAK inhibitors in the treatment of myelofibrosis.
Back
Optimizing Early Intervention and Combination Strategies in Myelofibrosis
Prithviraj Bose, MD, and Pankit Vachhani, MD, discuss the exploration of combination treatment approaches in myelofibrosis.
Optimizing Early Intervention and Combination Strategies in Myelofibrosis
Episodes
All
All
Prithviraj Bose, MD, and Pankit Vachhani, MD, discuss the importance of early intervention and when to initiate treatment in myelofibrosis.
Prithviraj Bose, MD, and Pankit Vachhani, MD, discuss the mechanism of action of selinexor and the rationale for investigating the agent in myelofibrosis.
Prithviraj Bose, MD, and Pankit Vachhani, MD, overview the phase 3 SENTRY trial evaluating selinexor plus ruxolitinib in JAK inhibitor–naive myelofibrosis
Prithviraj Bose, MD, and Pankit Vachhani, MD, discuss the key objectives of the phase 3 SENTRY trial evaluating selinexor plus ruxolitinib in JAK inhibitor–naive myelofibrosis.
Prithviraj Bose, MD, and Pankit Vachhani, MD, discuss how selinexor plus ruxolitinib could affect the frontline myelofibrosis treatment paradigm.
Prithviraj Bose, MD, and Pankit Vachhani, MD, discuss how future
Advertisement
Advertisement
Trending on OncLive
1
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma
4
Dr Carlino on 5-Year Data With Intismeran Plus Pembrolizumab in Resected Melanoma
5